EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis Reports Positive Results from Phase 2 Extension Study in Progressive Multiple Sclerosis Treated with NG-01 Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by NeuroGenesis

    Menu

    NeuroGenesis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NeuroGenesis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeuroGenesis Reports Positive Results from Phase 2 Extension Study in Progressive Multiple Sclerosis Treated with NG-01 Cell Therapy

              Details:

              NG-01 is a proprietary population of autologous bone marrow-derived stem cells designed to secrete high levels of remyelinating and neurotrophic factors (NG-01) at the central nervous system site of injury. It is being evaluated for the treatment of multiple sclerosis.

              Lead Product(s): NG-01

              Therapeutic Area: Neurology Product Name: NG-01

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeuroGenesis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy

              Details:

              Results published in Stem Cells Translational Medicine show significant reduction of NF-L, a biomarker for neuronal damage, in patients with progressive multiple sclerosis after treatment with NG-01 stem cells.

              Lead Product(s): Mesenchymal Stem Cells

              Therapeutic Area: Neurology Product Name: NG-01

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Hadassah Medical Center

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY